Cargando…

Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland

Long-acting injectable antipsychotics (LAIs) offer many benefits to patients with schizophrenia spectrum disorder (SSD). They are used with very different frequencies due to questions of eligibility or patients and prescribers’ attitudes towards LAI use. We assessed the prescribing rates of LAIs in...

Descripción completa

Detalles Bibliográficos
Autores principales: Reymann, Stephan, Schoretsanitis, Georgios, Egger, Stephan T., Mohonko, Alexey, Kirschner, Matthias, Vetter, Stefan, Homan, Philipp, Seifritz, Erich, Burrer, Achim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955244/
https://www.ncbi.nlm.nih.gov/pubmed/35330441
http://dx.doi.org/10.3390/jpm12030441
_version_ 1784676289673691136
author Reymann, Stephan
Schoretsanitis, Georgios
Egger, Stephan T.
Mohonko, Alexey
Kirschner, Matthias
Vetter, Stefan
Homan, Philipp
Seifritz, Erich
Burrer, Achim
author_facet Reymann, Stephan
Schoretsanitis, Georgios
Egger, Stephan T.
Mohonko, Alexey
Kirschner, Matthias
Vetter, Stefan
Homan, Philipp
Seifritz, Erich
Burrer, Achim
author_sort Reymann, Stephan
collection PubMed
description Long-acting injectable antipsychotics (LAIs) offer many benefits to patients with schizophrenia spectrum disorder (SSD). They are used with very different frequencies due to questions of eligibility or patients and prescribers’ attitudes towards LAI use. We assessed the prescribing rates of LAIs in a large academic psychiatric hospital with a public service mandate in Switzerland and compared them with other countries and health care systems. To our knowledge, this study is the first to investigate inpatient LAI use in Europe. Medical records of all patients diagnosed with SSD discharged from the Clinic of Adult Psychiatry of the University Hospital of Psychiatry Zurich over a 12 month period from January to December 2019 were evaluated regarding the prescribed antipsychotics at the time of discharge. The rates of use of LAIs among all patients and among patients receiving LAI-eligible antipsychotic substances were assessed retrospectively. We assessed records of 885 patients with SSD. Among all cases, 13.9% received an LAI. Among patients who received antipsychotic medication that was eligible for LAI use (n = 434), 28.1% received an agent as an LAI. LAI use included paliperidone palmitate (69.9%), aripiprazole monohydrate (14.6%), risperidone (4.9%) and first-generation LAIs (9.8%). Compared to international frequencies of LAI administration, the prescription rate of LAIs in SSD patients was low. Further studies will evaluate patient- and prescriber-related reasons for this low rate.
format Online
Article
Text
id pubmed-8955244
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89552442022-03-26 Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland Reymann, Stephan Schoretsanitis, Georgios Egger, Stephan T. Mohonko, Alexey Kirschner, Matthias Vetter, Stefan Homan, Philipp Seifritz, Erich Burrer, Achim J Pers Med Article Long-acting injectable antipsychotics (LAIs) offer many benefits to patients with schizophrenia spectrum disorder (SSD). They are used with very different frequencies due to questions of eligibility or patients and prescribers’ attitudes towards LAI use. We assessed the prescribing rates of LAIs in a large academic psychiatric hospital with a public service mandate in Switzerland and compared them with other countries and health care systems. To our knowledge, this study is the first to investigate inpatient LAI use in Europe. Medical records of all patients diagnosed with SSD discharged from the Clinic of Adult Psychiatry of the University Hospital of Psychiatry Zurich over a 12 month period from January to December 2019 were evaluated regarding the prescribed antipsychotics at the time of discharge. The rates of use of LAIs among all patients and among patients receiving LAI-eligible antipsychotic substances were assessed retrospectively. We assessed records of 885 patients with SSD. Among all cases, 13.9% received an LAI. Among patients who received antipsychotic medication that was eligible for LAI use (n = 434), 28.1% received an agent as an LAI. LAI use included paliperidone palmitate (69.9%), aripiprazole monohydrate (14.6%), risperidone (4.9%) and first-generation LAIs (9.8%). Compared to international frequencies of LAI administration, the prescription rate of LAIs in SSD patients was low. Further studies will evaluate patient- and prescriber-related reasons for this low rate. MDPI 2022-03-11 /pmc/articles/PMC8955244/ /pubmed/35330441 http://dx.doi.org/10.3390/jpm12030441 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Reymann, Stephan
Schoretsanitis, Georgios
Egger, Stephan T.
Mohonko, Alexey
Kirschner, Matthias
Vetter, Stefan
Homan, Philipp
Seifritz, Erich
Burrer, Achim
Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland
title Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland
title_full Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland
title_fullStr Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland
title_full_unstemmed Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland
title_short Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland
title_sort use of long-acting injectable antipsychotics in inpatients with schizophrenia spectrum disorder in an academic psychiatric hospital in switzerland
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955244/
https://www.ncbi.nlm.nih.gov/pubmed/35330441
http://dx.doi.org/10.3390/jpm12030441
work_keys_str_mv AT reymannstephan useoflongactinginjectableantipsychoticsininpatientswithschizophreniaspectrumdisorderinanacademicpsychiatrichospitalinswitzerland
AT schoretsanitisgeorgios useoflongactinginjectableantipsychoticsininpatientswithschizophreniaspectrumdisorderinanacademicpsychiatrichospitalinswitzerland
AT eggerstephant useoflongactinginjectableantipsychoticsininpatientswithschizophreniaspectrumdisorderinanacademicpsychiatrichospitalinswitzerland
AT mohonkoalexey useoflongactinginjectableantipsychoticsininpatientswithschizophreniaspectrumdisorderinanacademicpsychiatrichospitalinswitzerland
AT kirschnermatthias useoflongactinginjectableantipsychoticsininpatientswithschizophreniaspectrumdisorderinanacademicpsychiatrichospitalinswitzerland
AT vetterstefan useoflongactinginjectableantipsychoticsininpatientswithschizophreniaspectrumdisorderinanacademicpsychiatrichospitalinswitzerland
AT homanphilipp useoflongactinginjectableantipsychoticsininpatientswithschizophreniaspectrumdisorderinanacademicpsychiatrichospitalinswitzerland
AT seifritzerich useoflongactinginjectableantipsychoticsininpatientswithschizophreniaspectrumdisorderinanacademicpsychiatrichospitalinswitzerland
AT burrerachim useoflongactinginjectableantipsychoticsininpatientswithschizophreniaspectrumdisorderinanacademicpsychiatrichospitalinswitzerland